The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Ascendis Pharma reported positive two-year data for achondroplasia treatment. Data from the ApproaCH trial, announced on March 16, showed consistent growth improvement in children with achondroplasia using TransCon CNP. Further improvement in body proportionality was observed during the second year of weekly treatment.